Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter.
Klaire ExarchouHaiyi HuNathan A StephensAndrew R MooreMark KellyAngela LamarcaWasat MansoorRichard HubnerMairéad G McNamaraHoward SmartNathan R HowesJuan W ValleDavid Mark PritchardPublished in: Endocrine (2022)
Patients with ≤10 mm type I g-NENs were unlikely to develop clinically significant tumour progression and in most cases, resection was not needed. The endoscopic surveillance interval could therefore potentially be safely increased to every 2-3 years in such patients. However, lifelong surveillance is still advocated due to the additional risk of developing gastric adenocarcinoma.